Nexstim Oyj (STU:5NX) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5NX Nexstim Oyj STU:5NX
61 GF Score
Price €9.45
GF Value €8.18
! 5 Warning Signs
View Full Analysis

What is Nexstim Oyj Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Nexstim Oyj is: No Data: Cannot be evaluated.

Nexstim Oyj  (STU:5NX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Nexstim Oyj Risk Assessment Related Terms

STU:5NX vs ABT, SYK, MDT: Risk Assessment Comparison

For the Medical Devices subindustry, Nexstim Oyj's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nexstim Oyj Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexstim Oyj's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Nexstim Oyj's Risk Assessment falls into.


STU:5NX
61GF Score
Nexstim Oyj STU:5NX
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nexstim Oyj (STU:5NX) Overvalued in 2026?

Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued. The current stock price of €9.45 is trading 15.5% above its estimated GF Value™ of €8.18.

Key valuation signals for STU:5NX:

  • Risk Assessment:
  • GF Value™: €8.18 vs. price of €9.45 (15.5% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the STU:5NX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nexstim Oyj Business Description

Other Exchanges NXTMH:Finland5NX:Germany
Address Elimaenkatu 9 B, Helsinki, FIN, 00510
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
61GF Score

Get the complete analysis for STU:5NX

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.45
Price
€8.18
GF Value